• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

    10/20/23 9:00:00 AM ET
    $ASPI
    $SNGX
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASPI alert in real time by email

    ORLANDO, FL / ACCESSWIRE / October 20, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and Soligenix, Inc. (NASDAQ:SNGX) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • ASP Isotopes: https://www.redchip.com/assets/access/aspi_access
    • Soligenix: https://www.redchip.com/assets/access/sngx_access

    Paul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isotopes successfully acquired two incomplete ASP plants in Pretoria, South Africa, and obtained the required licenses from the nuclear regulators, including the Non-proliferation Council of South Africa, to complete construction of the plants and produce commercial product. Cold commissioning of the first manufacturing plant, capable of enriching light isotopes, was completed in Q1 2023, and ASP Isotopes entered into a Memorandum of Understanding with a North American customer for the entire offtake of the Company's first light isotope plant. The Company intends to enter into "take or pay" style offtake agreements with customers, and by 2028, ASP Isotopes expects to be a leading supplier of nonnuclear enriched isotopes generating over $150M in EBITDA per annum. ASP Isotopes has secured multiple supply agreements, including a 25- year agreement valued at up to $27M per annum with BRICEM (Beijing Research Institute of Chemical Engineering Metallurgy) to supply highly enriched Molybdenum-100 (Mo-100); a multi-year agreement with a Canadian company valued at $3.8M per annum for C-14, the most frequently used radiolabel healthcare; a $9M supply agreement with a US customer for a highly enriched isotope - customer made a $900k prepayment during Q3 2023; and an MOU for HALEU - $30 billion of HALEU demand expected based on initial discussions with customers.

    Also appearing on the RedChip Small Stocks Big Money® Show this week is Dr. Chris Schaber, CEO of Soligenix. Soligenix, a late-stage biopharmaceutical company, offers a robust pipeline of multiple fast-track and orphan-designated products with the potential for significant commercial returns of approximately $2 billion in global annual sales. Soligenix's late-stage clinical assets include HyBryte™ (SGX301), a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). The positive statistically significant results achieved in the Phase 3 study of HyBryte have been published in JAMA Dermatology, and the Company is preparing to meet with the FDA to discuss the design of the second confirmatory Phase 3 study. The estimated global market potential for HyBryte is $250 million, making it a significant commercial opportunity in an area of unmet medical need.

    About ASP Isotopes Inc.

    ASP Isotopes Inc. is an advanced materials company dedicated to developing technology and processes to produce isotopes in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process ("ASP technology"), for the production of all isotopes. The Company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).

    There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.

    About Soligenix

    Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).

    Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

    For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Small Stocks Big Money® Show is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Small Stocks Big Money® Show," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
    Follow RedChip on Twitter: https://twitter.com/RedChip
    Follow RedChip on YouTube: https://www.youtube.com/@redchip
    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    SOURCE: RedChip Companies Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/794956/asp-isotopes-and-soligenix-interviews-to-air-on-the-redchip-small-stocks-big-moneyr-show-on-bloomberg-tv

    Get the next $ASPI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPI
    $SNGX

    CompanyDatePrice TargetRatingAnalyst
    ASP Isotopes Inc.
    $ASPI
    10/4/2024$4.50Buy
    Canaccord Genuity
    ASP Isotopes Inc.
    $ASPI
    12/5/2023$3.25Buy
    H.C. Wainwright
    More analyst ratings

    $ASPI
    $SNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on ASP Isotopes with a new price target

    Canaccord Genuity initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $4.50

    10/4/24 7:13:36 AM ET
    $ASPI
    Major Chemicals
    Industrials

    H.C. Wainwright initiated coverage on ASP Isotopes with a new price target

    H.C. Wainwright initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $3.25

    12/5/23 7:36:42 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    $SNGX
    SEC Filings

    View All

    SEC Form 144 filed by ASP Isotopes Inc.

    144 - ASP Isotopes Inc. (0001921865) (Subject)

    9/8/25 9:00:13 PM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. filed SEC Form 8-K: Leadership Update

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    9/8/25 9:20:21 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    9/2/25 9:34:17 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    $SNGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of Managers of Quantum Leap Energy LLC

    WASHINGTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of managers of Quantum Leap Energy LLC. Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadership roles spanning strategy, operations, and innovation, and he brings expertise in nuclear technology development and commercialization, energy systems, and market development. Mr. Hun

    9/8/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

    PRINCETON, N.J., Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, Ph.D., President and Chief Executive Officer, has been invited to deliver a corporate presentation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held September 8 - 10, 2025 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Friday, September 5th at 7:00 AM ET. The presentation will be available f

    9/2/25 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ASP Isotopes Issues Letter to Shareholders

    WASHINGTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Mann. Dear Fellow Shareholder, The past few months have been exciting and highly rewarding as the Company has brought three isotope enrichment facilities into operation. I am delighted to report that the Company has now shipped the first samples of both Ytterbium-176 and Silicon-28 to customers, a major milestone for the Company that should allo

    9/2/25 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    $SNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:49 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:33 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Large owner Ak Jensen Investment Management Ltd bought $515,088 worth of shares (161,849 units at $3.18) (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/10/24 5:59:47 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    $SNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moore Duncan sold $696,232 worth of shares (75,000 units at $9.28), decreasing direct ownership by 7% to 994,553 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    9/3/25 5:40:33 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form 4 filed by Director Lapointe Anthony Gregg

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    6/20/25 4:34:32 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Zeldis Jerome B

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    6/20/25 4:27:00 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $SNGX
    Leadership Updates

    Live Leadership Updates

    View All

    Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of Managers of Quantum Leap Energy LLC

    WASHINGTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of managers of Quantum Leap Energy LLC. Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadership roles spanning strategy, operations, and innovation, and he brings expertise in nuclear technology development and commercialization, energy systems, and market development. Mr. Hun

    9/8/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Issues Letter to Shareholders

    WASHINGTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Mann. Dear Fellow Shareholder, The past few months have been exciting and highly rewarding as the Company has brought three isotope enrichment facilities into operation. I am delighted to report that the Company has now shipped the first samples of both Ytterbium-176 and Silicon-28 to customers, a major milestone for the Company that should allo

    9/2/25 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. Announces Expected Commencement of Dual Listing on Johannesburg Stock Exchange

    WASHINGTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided an update on its application to list on the Johannesburg Stock Exchange ("JSE"). The JSE has approved the listing of the Company's common stock on the Main Board of the JSE under the abbreviated name "ASPI", share code "ISO" and international securities identification number US00218A1051, with commencement of trading expected on Wednesday, August 27, 2025. The Company will retain its primary listing on the Nasdaq Cap

    8/8/25 9:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    $SNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ASP Isotopes Inc.

    SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

    11/14/24 3:01:19 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by ASP Isotopes Inc.

    SC 13G/A - ASP Isotopes Inc. (0001921865) (Subject)

    11/7/24 4:15:14 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by ASP Isotopes Inc.

    SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

    11/3/23 4:15:20 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    $SNGX
    Financials

    Live finance-specific insights

    View All

    ASP Isotopes Inc. Hosts South African Investors in Advance of Secondary Listing on the Johannesburg Stock Exchange (JSE) and Provides Updates on its Isotope Production Plants

    - ASP Isotopes will host an investor access event on Tuesday, August 26, 2025 at its Pretoria facilities for approximately 30 South African investors. - ASP Isotopes expects to have a secondary listing on the Johannesburg Stock Exchange (JSE) and its common stock is expected to commence trading on the JSE on Wednesday, August 27, 2025. - ASP Isotopes has shipped its first samples of enriched Silicon-28 to a US-based customer and expects to complete the enrichment of the first samples of Ytterbium 176 during August 2025. - ASP Isotopes Management Team will feature on a RedChip Investor call at 4:15 pm EDT on Thursday, August 28, 2025. Ryno Pretorius, CEO of Quantum Leap Energy, and Stefano

    8/26/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment

    - IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. - IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. (ASPI). - The strategic collaboration contemplates future manufacturing opportunities for PET Labs (ASPI's nuclear medicine subsidiary). - IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturi

    7/28/25 8:31:17 AM ET
    $ASPI
    $IMNM
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (NASDAQ:NVA) and Soligenix Inc. (NASDAQ:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nova Minerals: https://www.redchip.com/assets/access/nva_accessSoligenix: https://www.redchip.com/assets/access/sngx_accessChristopher Gerteisen, CEO of Nova Minerals, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Nova Minerals p

    9/20/24 9:00:00 AM ET
    $BOXL
    $NVA
    $SNGX
    Other Consumer Services
    Real Estate
    Precious Metals
    Basic Materials